drugset / Trial / NCT00673790

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

NCT00673790

Phase 4 Completed 537 enrolled Forest Laboratories
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being done to see if the blood pressure and metabolic effects of an approved drug nebivolol is comparable to that of another approved drug hydrochlorothiazide (HCTZ) and placebo in hypertensive patients.

Timeline

Start
2008-05-15
Primary completion
2010-07-09
Completion
2010-07-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrochlorothiazide Unknown 12.5 mg Oral
Comparator Hydrochlorothiazide Unknown 25 mg Oral
Comparator Nebivolol Other / unclassified 5 mg Oral
Comparator Nebivolol Other / unclassified 10 mg Oral
Comparator Nebivolol Other / unclassified 20 mg Oral
Comparator Nebivolol Other / unclassified 40 mg Oral
Comparator LISINOPRIL ANHYDROUS Small molecule 10 mg Oral
Comparator Losartan Other / unclassified 50 mg Oral

Indications